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Abstract 
Radical treatments such as prostatectomy and radiotherapy have demonstrated 
success in terms of biochemical and disease-specific survival for localised prostate 
cancer. However, whilst the end goal of any cancer treatment is to control or cure 
disease it must also do so by minimising any side effects that may be experienced by 
the patient. Focal therapy as a concept aims to redress this established therapeutic 
ratio by treating areas of the prostate affected by significant disease as opposed to 
treating the entire gland. However, there are a number of common criticisms of 
focal therapy - we deem the seven sins - that require further interrogation. 
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Introduction 
Radical treatments such as prostatectomy and radiotherapy have demonstrated 
success in terms of biochemical and disease-specific survival for localised prostate 
cancer[1-3]. However, whilst the end goal of any cancer treatment is to control or 
cure disease it must also do so by minimising any side effects that may be 
experienced by the patient. Focal therapy as a concept aims to redress this 
established therapeutic ratio by treating areas of the prostate affected by significant 
disease as opposed to treating the entire gland. However, there are a number of 
common criticisms of focal therapy – we deem the seven sins – that require further 
interrogation and summarised in table 1. 
Reason 1 - ‘Prostate cancer is multifocal’ 
This is true. Studies of whole-mount prostate specimens have demonstrated that in 
the majority of cases, multifocal disease is present[4]. However, in 15% of men the 
disease is truly unifocal4. Despite this, multifocality in itself need not preclude focal 
therapy considering the biology of the disease and its status as an outlier in solid 
organ cancer therapy. Prostate cancer is largely isolated where radical therapy 
remains the gold standard treatment. By comparison, despite initial and stalwartly 
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held beliefs, the last two decades have seen the widespread acceptance of subtotal 
thyroidectomy, partial nephrectomy, partial penectomy, subtotal pancreatectomy 
and lumpectomy in breast cancer in preference to their more radical counterparts.  
Breast surgeons have, in recent years, made great efforts to focus the treatment of 
breast cancer on the tumour rather than the whole breast. This is clearly reflected in 
wide local excision replacing the radical mastectomy as the primary treatment for 
ductal breast carcinoma. This was reported as early as 1992[5] despite up to 75% of 
these malignancies being multifocal6. Naturally, concerned voices dissented[7].  
Many argue that breast cancer is no similar to prostate cancer as adjuvant 
radiotherapy still targets the whole breast after wide local excision. However, more 
recent studies have demonstrated that the tumour focused approach to treatment 
has equivalence in outcome when compared to a more radical approach.  For 
example, a randomized controlled trial built on established knowledge that even in 
the presence of multifocality, 90% of local recurrences occur in the index quadrant. 
The trial compared targeted intraoperative radiotherapy to external beam 
radiotherapy following breast-conserving surgery[8]. No difference was found in 
tumour recurrence between the groups[8]. Indeed, overall survival was slightly 
better in the targeted radiotherapy arm due to a reduction in radiation-induced 
toxicity to the heart and lungs[8]. 
Similarly, the treatment of renal cell carcinoma has seen a clear shift from radical 
nephrectomy to nephron sparing surgery. Much like with breast cancer there was 
initial controversy. Authors called for the re-evaluation of the indications for partial 
nephrectomy due to the presence of satellite lesions or nodules found in whole 
organ pathology specimens[9], which would be left behind following nephron-
sparing surgery. Once again, evidence of overall survival equivalence began to build 
until a randomised controlled trial (RCT) of 541 patients demonstrated no significant 
difference in overall survival between patients undergoing partial or radical 
nephrectomy for renal cell carcinoma[10]. It is of interest, that practise and guidelines 
had changed many years prior to this RCT based on prospective cohort studies.  
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Thus, in both these examples the suggestion is that lesions which are inevitably left 
behind by a more focal or less aggressive treatment do not go on to metastasise, or 
at least not within a significant period of time. In prostate cancer there is now clear 
evidence that (on the whole) it is the largest, highest grade index lesion that drives 
the progression to local invasion and metastases. First, one can look at the 
histological prognostic characteristics observed in whole-mount prostate specimens.  
When extracapsular extension or seminal vesicle invasion is present, it is 
predominately within the index lesion. Karavitakis et al demonstrated that where 
these features are seen in satellite lesions, they are also high grade and high 
volume[11]. In their analysis of 100 radical prostatectomy specimens they showed 
that whilst the majority of specimens had multifocal (78%), or bilateral (86%) 
disease, 99.4% of these satellite lesions were of Gleason 6 grade or less and 87% 
were less than 0.5ml in volume[11]. Furthermore, when Bott et al investigated the 
tumour volume and its relationship with tumour grade, most high-grade disease, i.e. 
Gleason 7 or higher, resided in larger volume tumours[12]. However, Gleason 7 or 
higher disease was also found in 10% of <0.5ml tumours and 5% of <0.2ml 
tumours[12]. In these cases however, the grade was predominantly Gleason 3+4[12].   
When one delves deeper, from the microscopic to the molecular level, there is clear 
evidence that it is the index lesion that drives the metastatic process. In other words, 
the genomic profiles of prostate cancers and their metastases imply that the latter 
originate from a single clone[13]. Liu et al demonstrated from their genomic analysis 
of 85 tumour sites in 29 men, that the metastases were likely to have a common 
clonal origin[14]. However, they could not link them to individual lesions within the 
prostate itself[14]. Likewise, the importance of TMPRSS2-ERG fusion in prostate 
cancer has been documented for some time[15]. More relevant to this arena 
however, is the concordant presence of this abnormality in both the index lesion and 
lymph node metastases[16] and multiple metastases exhibiting TMPRSS2 
aberrations of indistinct molecular subtypes[17]. We can conclude from these 
observations that metastatic deposits in prostate cancer originate from a single 
precursor cancer cell[14,16,17] and that these are most likely to arise from the index 
lesion in multifocal disease[16]. 
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Regardless, one could ask what the clinical implications are for these observations.  
The inference is that low grade; low volume disease does not need to be treated. In 
addition to these histological and molecular studies there is now substantial, and 
perhaps more tangible, clinical evidence to support this. In particular, there is now 
strong evidence that low grade disease is unlikely to lead to metastasis and death. 
For example, Ross et al in a study of 14000 aimed to determine whether or not in 
men with pure Gleason 6 cancer, their disease had the potential to metastasise[18]. 
In each of the 22 cases of lymph node metastasis, a review of their whole mount 
specimens found that they all had higher-grade disease[18]. The authors remarked 
“it can now be concluded that GSr6 using the updated system lacks the potential to 
metastasise to pelvic lymph nodes”[18]. Klass et al reported on a prospective cohort 
of 1300 men with low risk prostate cancer[19]. Of this group, only 93 (7%) had died 
from their disease at 15 years of follow-up[19]. This suggests that whilst low-risk, 
these cases still convey some mortality. However, further evidence suggests that 
such mortality is due to errors in risk stratification at diagnosis. Eggener et al in a 
study investigating the long-term outcomes in a retrospective cohort of 9557 men 
who underwent surgery for pure Gleason 6 disease, regardless of tumour 
volume[20]. In this group only three died over a 15-year period[20]. However, when 
the pathological specimens were re-examined in these men, they all had higher-
grade disease, which had initially been overlooked[20]. Thus, of 9554 men, none 
died from their prostate cancer within 15 years[20]. This suggests that whilst low-
risk, these cases still convey some mortality. However, further evidence suggests 
that such mortality is due to errors in risk stratification at diagnosis. Such is this 
weight of evidence for low volume Gleason 6 disease behaving in an indolent 
manner that a number of groups have advocated its re-designation as a benign 
entity[21]. 
However, conflicting evidence might exist, in rare instances. For example, a single 
case report by Haffner et al described whole-genome sequencing of metastatic 
deposits in a man who died from lethal, metastatic prostate cancer 17 years after 
diagnosis22. This defined the genetic characteristics of the lethal disease.  This was 
then compared to the whole mount prostatectomy specimen removed at surgery 17 
 7 
years previously. Unsurprisingly, there was substantial heterogeneity within the 
primary tumour[22]. It appeared that the lethal clone had arisen from a small focus 
of Gleason 6 disease surrounded by a larger area of high-grade disease[22]. The 
lymph node metastases also appeared to be from a different clonal origin[22]. 
Concern was rightly raised and asked questions regarding not only the index lesion 
hypothesis but also called into question the current dogma that these tumours do 
not develop lethal, metastatic potential. This man had died from disease that would 
be considered today as low-risk for progression[23]. This was touched upon by 
Barbieri et al who argued, after examining the prostatectomy specimen, that several 
areas of the gland contained the same SPOP-mutation, alongside significant 
proportions of Gleason 4 disease, and these are likely to be the same tumour24. They 
concluded that in this case, the lethal tumour began “as a relatively large, SPOP-
mutant tumor displaying significant amounts of Gleason pattern 4”[24]. Most 
importantly, the presence of a small focus of Gleason 6 tumour within a larger 
volume high-grade tumour would not have had implications on clinical decision 
making[24] and certainly was not the same as a single tiny focus of Gleason 6 disease 
on its own. Were that to be the case, and taking the arguments proposed by some 
authors that we should be cautious if leaving Gleason 6 disease untreated[25], one-
third of the male population would need to have a prostatectomy – a clearly 
ridiculous notion. A similar picture emerged from a case report from the Johns 
Hopkins University once again. Haffner et al described a man who chose to enter 
active surveillance for low grade, low volume prostate cancer, who subsequently 
developed high grade, high volume disease, which he consequently died from[26]. 
Immunohistochemical staining revealed positivity for ERG and TP53, which was not 
shared by the earlier biopsy core taken during active surveillance[26]. Furthermore, 
the Ki-67 proliferation index was low for the cores during active surveillance but 
dramatically higher in the later, high-grade biopsy[26]. They concluded that rather 
than this case demonstrating lethal progression from the initially diagnosed tumour, 
the lethal disease arose from a clonally distinct anterior tumour, which was not 
sampled on TRUS biopsy[26]. This supports our position that not all lesions are 
clinically important in terms of progression and lethality. In yet another example, 
Grasso et al showed in a case report of a man with coeliac lymph nodes metastases, 
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lung metastases and bladder metastases that a Gleason 9 tumour identified on a 
whole-mount prostatectomy specimen was the monoclonal origin of the disease 
process[27]. Once again, this supports our position, namely that progressive disease 
derives from a single point of origin. These are n=1 case reports and as such lack 
significant weight, despite being intriguing anecdotes. However, studies investigating 
the genomic basis of prostate cancer and the natural evolution of the disease 
process will inevitably add far greater insight.   
With what we now know, can we truly state that the multifocal nature of prostate 
cancer renders focal therapy ineffectual? If it is rare, but not impossible, for men 
with pure Gleason 6 disease to metastasise, is it too great a leap to propose that 
secondary lesions in a man with a clinically significant index lesion will also rarely 
metastasise?   
Reason 2 – ‘You cannot accurately localise prostate cancer lesions.’ 
Whilst this might be true of the TRUS biopsy which we know gets the grade or side of 
cancer wrong in between 30-50% of cases with low risk or unilateral cases, 
respectively[28], as things stand currently, we have excellent diagnostic tools that 
are not only highly sensitive at detecting cancer within the prostate, but also 
accurately determine the locality of disease within the gland. Firstly, there is 
transperineal template mapping biopsy. Appropriate criticisms have been made of 
the technique, of course. These include the risk of over diagnosis, additional burdens 
on patients and healthcare systems and a steeper learning curve for clinicians to 
climb as well as costs and resource issues. However, the ability of the technique to 
accurately localise disease within the prostate might outweigh these 
disadvantageous caveats.  
For example, computer simulation has demonstrated that mapping biopsy is far 
more accurate than the transrectal biopsy[28]. These simulations, performed on 107 
whole mount prostatectomy reconstruction models demonstrated that transperineal 
mapping biopsy missed only 5% of tumours >/=0.2mL and >/=0.5mL compared to 
30-40% in traditional transrectal biopsy[28]. Optimised transrectal biopsy strategies 
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were better than standard transrectal biopsy, but still inferior to transperineal 
mapping strategies[28]. Clearly, we still, as a professional community base our 
pathway on a demonstrably poor test. Furthermore, Crawford et al, in direct 
comparison of 25 men who underwent transperineal mapping biopsies with their 
reconstructed whole mount prostatectomy specimens following surgery showed 
that this biopsy strategy was highly accurate[29]. Indeed, of 64 tumours only a single 
significant Gleason 8 0.02mL tumour was missed at biopsy[29]. However, as we have 
previously mentioned transperineal mapping biopsies do carry disadvantages and 
additionally, once identified and localised, how can we stratify the risk of potential 
lethality for each patient? We would advocate a system that takes into account the 
Gleason grade, and the lesion volume derived from the surrogate measurement of 
maximum cancer core length. One such example is our own UCL criteria, i.e. 
definition one being the presence of Gleason >/=4+3 and/or maximum cancer core 
length >/=6mm and definition two was the presence of Gleason >/=3+4 and/or 
maximum cancer core length >/=4mm[28]. Gleason </=6 and/or </=3mm maximum 
cancer core length are viewed as insignificant disease (figure 1)[28]. This is one way 
forward, to stratify the risk of individual lesions within the prostate, rather than the 
whole gland itself. The strongest application of this combined mapping biopsy and 
focal risk stratification technique is just that, a risk stratification map of the prostate 
gland (figure 2). 
In addition, do we yet have at our disposal, imaging technology that can accurately 
localise cancer within the prostate? The development of such a tool would clearly 
revolutionise the diagnosis of prostate cancer. After all, prostate cancer stands alone 
as the sole solid organ malignancy where targeted biopsies based upon imaging are 
not standard practice. With regard to this situation Dr Patrick Walsh stated in 2008, 
“To the young people here, if you want to make a substantial contribution to 
medicine for this decade and maybe for the century, address yourself to the problem 
of imaging of cancer within the prostate gland”[30]. This is one of the fastest 
growing fields in prostate cancer and we have undeniably made great strides here.   
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We know that multiparametric MRI (mpMRI) can show discrete lesions within the 
prostate (figure 3) and that its negative predictive value (NPV) of is excellent, 
especially for significant disease[31]. Studies have compared mpMRI against 
examination of whole mount prostate specimens. For example, Villiers et al 
demonstrated a sensitivity, specificity, positive and negative predictive value of 77%, 
91%, 86% and 85% for tumour foci of >0.2mL, and 90%, 88%, 77% and 95% for 
tumour foci of >0.5mL respectively when dynamic contrast enhancement is added to 
the MRI sequence protocol[32]. In an update from this group, sensitivity and 
specificity of 86% and 94% was reported for >0.5mL tumours[33]. Such findings are 
replicated in the systematic review by Futterer et al which found that mpMRI had 
detected clinically significant disease in 44% to 87% of men and had a negative 
predictive value of 63% to 98% where prostate biopsy or whole mount 
prostatectomy specimens were used as the reference standard[31]. It is not a 
perfect diagnostic test as it misses some high volume Gleason 6 or low volume 
Gleason 7 and very rarely higher grade disease[34]. Compared to our current 
standard of care upon which we make treatment decisions and which is 30-50% 
inaccurate, it is substantially better[28]. 
Studies have also compared the diagnostic accuracy of mpMRI against transperineal 
template mapping biopsy. This study design is particularly useful, as they so not 
apply a selection bias to the population. One example is Arumainayagam et al in 
2013.  They showed, as we know, that for the detection of any cancer mpMRI is a 
poor test with a NPV of between 60% and 63%[35]. However, when thresholds of 
histological risk are applied the results are excellent. For Gleason >/=3+4 disease 
and/or a maximum cancer core length >/=4mm the NPV was between 85% and 
90%[35]. For Gleason >/=4+3 and/or a maximum cancer core length of >/=6mm the 
NPV was 93% to 97%[35]. Naturally these levels of risk must be applied to an 
individual patient, their expectations and what level of risk they are willing to accept.  
Similar studies from numerous centres have demonstrated similar results[36-41]. 
However, not wishing to rest on the evidence we have already, the PICTURE[42] and 
PROMIS[43] trials are set to report in the near future. 
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Reason 3 – ‘Focal therapy ‘treats’ men who don’t need treatment.’ 
This is not entirely accurate nor does it apply to focal therapy alone. A systematic 
review from 2014 found 2350 cases of localised prostate cancer in 30 studies, which 
were treated with focal therapy[44].  Gleason score was reported in 13 studies and 
PSA was reported in 11[44]. According to the D’Amico risk classification[45], 
approximately half of cases treated had intermediate or high risk disease[44]. Our 
group are building on this.  In the prospective, investigator led INDEX trial, evaluating 
the efficacy of high intensity focussed ultrasound in the treatment of localised 
prostate cancer, we are now no longer including men with low volume Gleason 6 low 
risk disease[46]. The patients are free to elect for radical options but they will be 
excluded from undergoing focal therapy under our care. Additionally, although 
overtreatment of men with low risk disease with radical prostatectomy disease is 
falling, it still occurs[47]. Likewise, this occurrence is also seen, and more commonly 
so, with radical radiotherapy[48]. Indeed between 2004 and 2007 58% of men were 
treated with radical radiotherapy in comparison to less than 10% by active 
surveillance or watchful waiting[48]. 
Reason 4 – ‘For men who need treatment, radical therapy is effective so men and 
their physicians have to just accept the side effects.’ 
This argument may sound familiar. The urological community experienced a similar 
reaction to the introduction of partial nephrectomy. Some argued that the patients 
would cope less well after partial nephrectomy, as they would fear a higher risk of 
recurrence despite the reduction in inevitable side effects of radical nephrectomy. 
This was tested and shown to be untrue[49,50].  This position was also seen with 
breast cancer but once again, these concerns appear to have been unfounded[51]. 
We cannot solely act on our patients’ behalf in the out-dated paternalistic model of 
medicine. Men with prostate cancer are able and willing to make trade-offs when it 
comes to their treatment. We know that men are not willing to accept any side 
effect unless they receive a certain amount of life expectancy in return.  A discrete 
choice experiment in 2012 demonstrated this quite elegantly. The authors found 
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that if you give a man severe urinary blockage, bowel symptoms or urinary leakage, 
he will want around two years of life in return beyond a typical 12 years of life 
without having treatment[52]. If you render him impotent he will want four to six 
months of life in return[52]. As the authors of the discrete choice experiment stated, 
this “underlines the need to inform patients of long-term consequences and 
incorporate patient preferences into treatment decisions.[52]” 
Reason 5 – ‘Focal therapy has no better functional outcomes than modern radical 
surgery.’ 
There are two critical parts to this statement. Firstly, what does one mean by 
“modern radical surgery”? Secondly, does this ‘modern’ approach benefit patients in 
terms of their functional outcome? Function outcomes being erectile function and 
urinary incontinence and with radiotherapy, rectal toxicity. 
In regard to the first question, as things currently stand the robotic-assisted 
laparoscopic prostatectomy (RALP) might be regarded as the modern approach for 
the surgical management of localised prostate cancer. It has clearly replaced the 
open radical prostatectomy as the treatment of choice. The intraoperative blood loss 
and inpatient stay is demonstrably reduced with RALP[53], as is the immediate 
surgical morbidity[54]. However, there are many studies, some long term, reporting 
on the functional outcomes of prostatectomy and these have reported modest 
results which have been summarised in two pertinent systematic reviews. Firstly, 
Ficarra et al published systematic review of 51 articles in 2012 demonstrating 12 
month ‘no pad’ incontinence rates of 4% to 31%, or ‘no pad or safety pad’ 
incontinence rates of 8% to 11%[55]. Likewise, that group also performed a 
systematic review of potency following RALP. After analysing 31 studies they found 
12 to 24 month potency rates varied from 54% to 90% and from 63% to 94% 
respectively[56]. 
However, perhaps there were issues with user experience in these results.  We know 
that there is a significant learning curve associated with prostatectomy[57-58] and 
perhaps the results from the most experienced centres are better. Carlsson et al 
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reported on functional outcomes of 1280 men 18 months following surgery[59]. 
Using patient-related outcome measures, they demonstrated surgeon heterogeneity 
for continence, but not for sexual function[59]. However, the overall functional 
outcomes still comparable to the above studies with 18 month continence and 
potency rates of 85% and 19% respectively[59]. 
Of course, the discerning eye will have noticed that these studies report on radical 
prostatectomy rather than purely RALP. However, purely in terms of functional 
outcomes, the evidence that RALP bears advantages over open prostatectomy is 
wanting[60-62]. A systematic review by Finkelstein et al in 2010 found no convincing 
evidence that RALP offered a functional outcome advantage over open 
prostatectomy[60]. Haglind et al compared 778 open prostatectomies with 1847 
RALPs[61]. 56% of men who had open prostatectomies were not pad or leak free at 
12 months post surgery compared to 57% of those who underwent a RALP[61]. This 
difference was not significant.  The RALP fared marginally better in sexual function 
however with 30% being potent compared with 25% of men who had an open 
prostatectomy[61]. Likewise, Jackson et al found no significant difference in the 
functional outcomes at 10 years between open prostatectomy and RALP[61]. Short-
term results have demonstrated an improvement with RALP over open 
prostatectomy[63]. However, as things currently stand the evidence that modern 
surgery is better than open surgery in terms of functional outcomes is poor in itself. 
The functional outcomes of focal therapy compare rather well. Valerio et al in a 
systematic review found that in the studies using validated patient-related outcome 
measures that leak-free incontinence rates were 83% to 100%, the pad free 
incontinence rates were 95% to 100% and that 53% to 100% of men were able to 
maintain an erection sufficient for penetration without or without the use of a PDE5-
Inhibitor[64]. Rectal fistula rates were reported in between 0% and 1% of cases and 
usually occurred early in the learning curve[64]. Similarly, Yap et al found that 
although there is a significant fall in potency at one and three months post surgery, 
after that time there is no difference between the pre and postoperative degree of 
potency following focal HIFU[65]. 
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Long-term functional follow-up is still needed but from the evidence that is available 
to us, it cannot be stated the functional outcomes of modern radical surgery are the 
same as focal therapy.  
Reason 6 – ‘Treating less than the whole prostate risks leaving cancer behind, so 
you’re risking men’s lives.’ 
Once again, this is an argument we should all already be familiar with.  When the 
nerve sparing prostatectomy was developed, sceptics, with an amusing turn of 
phrase, declared, “The procedure is cancer-sparing surgery[66].” Some 
contemporaries felt at that time, that total prostatectomy should remain the optimal 
treatment for patients with localised cancer of the prostate[67]. It was through the 
meticulous work of Patrick Walsh in Johns Hopkins that it was demonstrated that 
nerve-sparing surgery was oncologically safe. In deed, based on this series of 100 
cases, an entire treatment modality shifted internationally[68]. We saw the same 
arguments regarding nephron-sparing surgery. For example, Wunderlich et al in 
1999 stated that the major disadvantage of nephron-sparing surgery for renal cell 
carcinoma is the risk of local recurrence[69]. Interestingly, this paper noted that in 
90% of cases of renal cell carcinoma, the disease was bilateral. We doubt that one 
would advocate bilateral radical nephrectomy even if the only concern were the risk 
of out of field disease recurrence. Not to mention that these fears were unfounded 
as was touched upon earlier[10]. 
Are these same concerns valid for focal therapy? The evidence available to us at this 
time suggests perhaps not. Bahn et al demonstrated in the follow-up of 73 men who 
had undergone cryotherapy for localised disease, that cancer control in the treated 
side of the gland was good[70]. In almost all men, based on year-on-year TRUS and 
targeted biopsy there was no recurrence of disease in the treated side[70]. Around 
40% of men would however, have biopsy positive disease at five years post 
surgery[70].  Likewise, Rouget et al reported on 191 patients who were treated for 
localised prostate cancer with high-intensity focussed ultrasound. At a mean follow-
up of 55·5 months the metastatic-free survival was 97·4%[71]. When one looks at 
the existing literature as a whole, then a similar picture emerges. In studies reporting 
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short to medium term follow-up, that on postoperative biopsy, the rates of any 
cancer being detected are between 3.7% and 23%, which falls to 0% to 17% when 
adjusted for clinical significance[64]. 0% to 33% require further whole gland therapy 
and as the follow-up lacks longevity the rates of metastasis or death from disease 
are 0% to 0.3%[44]. We argue that this evidence shows good disease control in the 
short to medium term. 
Reason 7 – ‘There is no data from randomised controlled trials’ 
No there is not. In fact there is little in the way of comparative data at all.  But one 
cannot ignore that our advocacy of the efficacy of radical prostatectomy is based on 
a single comparative study of radical prostatectomy versus no early intervention at 
all[71] even though a subsequent RCT showed no overall survival benefit in 
treatment compared to watchful waiting[72]. This is not a problem solely 
experienced by focal therapy, or even urology in general. The extent of the problems 
experienced in surgical comparative research cannot be understated. As we can see 
from the examples above, surgeons think they know best and patients usually want 
to have choice in their treatment. Our treatment of renal cell carcinoma once again 
can provide a pertinent example.  In 2010 the European Association of Urology 
published its guidelines for treating localised renal cell carcinoma. They stated, 
“Patients with low-stage RCC (T1) should undergo nephron sparing surgery. Radical 
nephrectomy is no longer the gold standard of treatment in these cases[73].” These 
were published before the EORTC randomised controlled trial comparing the 
oncological outcomes of the two techniques reported[74]. As a result the trial 
investigators lost equipoise.  As they stated three years previously when reporting 
on complications of the two techniques, “The oncologic results are eagerly awaited 
to confirm that NSS is an acceptable approach for small asymptomatic RCCs.” It was 
revealing that they wished to confirm the disease control outcomes and not discover 
it relative to nephrectomy. 
Can we improve on our similar predicament in prostate cancer? As things stand we 
have had some successes. However, the number of failures outweighs these.  
Invariably, our trials have failed either due to low patient recruitment, or lack of 
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physician equipoise[75].  We can, and must, keep making attempts to design trials 
that will gather good comparative data. However, rejecting focal therapy due to an 
issue that plagues all of surgery is not consistent with changes in practice that have 
been advocated and made based on non-comparative data. 
Conclusions 
Focal therapy is the next stage in surgical innovation for treating localised prostate 
cancer. As a paradigm shift, it reflects the biology of the disease. Prostate cancer is 
multifocal in the majority of cases. However, the biology of the disease makes not 
treating Gleason 6 lesions and therefore parts of the prostate a legitimate strategy.  
We do have the tools to accurately locate disease within the prostate, but these are 
not 100% accurate. Likewise we have the tools to treat focally and whilst these are 
not 100% effective, medium term outcomes demonstrate effectiveness with 
remarkably lower side-effect rates. Finally, we must continue to strive to develop 
large, multi-centre long term studies. 
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Figure and table legends 
Figure 1: The University College London histological risk stratification system. 
Figure 2: An example of a histological risk map derived from a template mapping 
biopsy; in this case using modified Barzell zones. 
Figure 3: An example of mpMRI demonstrating discrete identifiable lesions within 
the gland.  The lesion identified by the arrow is clearly visible in T2 weighted, ADC 
and DCE sequences. 
Table 1: A summary of the arguments for and against focal therapy in localised 
prostate cancer 
 
 
 
 
